Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global Oligonucleotide Aptamer Market Forecast, 2026-2032 - AI-Driven Discovery and Expanding Diagnostic and Therapeutic Applications Propel Market Toward USD 8.96 Billion by 2032Boost ROI with AI-assisted discovery, rigorous validation, early stability and delivery testing, quality controls, regional partnerships, and fit-for-purpose regulatory plans
- Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance InnovationCompanies: Thermo Fisher Scientific Inc.Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce training
- Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of DirectorsLift Therapeutics today announced the appointment of Eva Ehrnrooth as Executive Head of Clinical Development and Chau Khuong to its Board of Directors.
- Global Peptoids Market Forecast, 2026-2032 - AI-Enabled Discovery and Expanding Drug Delivery, Diagnostics, and Biomaterials Applications Drive 10.81% CAGR Toward USD 145.45 MillionBoost ROI by targeting validated applications, standardizing synthesis, using DOE and AI to prioritize R&D, partnering to close gaps, and addressing IP and regulation early.
- DJS Law Group LLPARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYThe DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
- Schall, Brown & Schwartz LLPSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the...
- SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP FinesLONDON, September 28, 2026--British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance.
- Schall, Brown & Schwartz LLPCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)...
- DJS Law Group LLPCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRThe DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
- SOLA Biosciences Japan GKSOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS PatientsSOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan...
- Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate UpdateDaix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.
- QIAGEN N.V.QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection PanelGERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S.